Seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC) , leukemia , HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders. Seliciclib is a 2,6,9-substituted purine analog. Its structure in complex with CDK2 was determined in 1996. [1] Seliciclib inhibits CDK2/E, CDK2/A, CDK7 and